EU orders up Valneva’s inactivated Covid-19 vaccine
The EU has secured 60 million doses of Valneva’s potential Covid-19 vaccine VLA2001. When approvied, it would be the first inactivated vaccine on the EU market.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 241 entries already.
Entries by Uta Mommert
Stock market boom: Two biotechs go public
Two European oncology biopharma companies have made the leap onto the stock market: French MaaT Pharma went public on Euronext Paris, while Danish IO Biotech chose Nasdaq Global Market for its IPO.
LSP raises a whopping €850m for the European life sciences
European life science investor LSP has raised €850m for its 7th generation flagship fund LSP 7.
AstraZeneca unloads respiratory drugs to Covis
Luxembourg-headquartered Covis is taking two COPD drugs off AstraZeneca’s hands in a US$270m deal.
Evotec goes for massive IPO on Nasdaq
German drug discovery company Evotec plans to raise US$576m on the US-American stock exchange Nasdaq to finance extensive investments.
€40m for Treg starver start-up
Institut Curie spin-off Egle Therapeutics has raised €40m in a Series A financing. The company will use the funds to develop First-In-Class T-regulatory cells therapies based on Treg starvers.
From make-up to jet fuel: Breakthrough for Global Bioenergies
The French company has taken big steps to scale up its process for converting plant-based feedstocks into isobutene, bringing affordable aviation biofuels into reach.
BICO raises €600m and acquires QInstruments
With €600m from a directed share issue in its coffers, BICO finalises the acquisition of QInstruments, a specialist in advanced sample preparation automation.
European sustainability fund raises €200m
The European Circular Bioeconomy Fund, initiated by the EU, has raised more than €200m that will be used to drive the transformation towards a bio-based economy.
Idorsia: Failure in Phase III
Bad news for Swiss drug discovery company Idorsia: Its Fabry disease hopeful lucerastat failed to reduce neuropathic pain in patients.